Author(s): Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, , Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G,
Abstract Share this page
Abstract In this randomized, placebo-controlled study, it was found that a 24-hour levosimendan infusion improves echocardiographic markers of abnormal left ventricular diastolic function (transmitral flow patterns and mitral annulus velocities, as assessed by transthoracic pulse-wave Doppler and tissue Doppler imaging, respectively) and reduces substances of excessive neurohormonal activation (plasma B-type natriuretic peptide and interleukin-6) in patients with advanced heart failure. Moreover, levosimendan-treated patients had fewer events and longer progression-free survival during a 5-month follow-up compared with those who received placebo. Thus, levosimendan seems to be effective in improving left ventricular diastolic function and reducing neurohormonal activation in patients with severe heart failure.
This article was published in Am J Cardiol
and referenced in Cardiovascular Pharmacology: Open Access